1. Survival impact of sequential chemotherapy following pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma
   Sho Iwaki et al, 2024, International Journal of Clinical Oncology CrossRef
2. Paclitaxel-encapsulated core–shell nanoparticle of cetyl alcohol for active targeted delivery through oral route
   Debabrata G Dastidar et al, 2019, Nanomedicine CrossRef
3. Research Progress and Prospect of Nanoplatforms for Treatment of Oral Cancer
   Zhilong Zhao et al, 2020, Frontiers in Pharmacology CrossRef
4. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
   Shinsuke Suzuki et al, 2021, Medicina CrossRef
5. Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
   Tomohiro Enokida et al, 2018, Frontiers in Oncology CrossRef
6. Progress in targeted therapeutic drugs for oral squamous cell carcinoma
   Lian Liu et al, 2019, Surgical Oncology CrossRef
7. Optimal Contact Concentration of Paclitaxel in the Collagen Gel Droplet-Embedded Culture Drug Sensitivity Test for Human Oral Squamous Cell Carcinoma and Evaluation of Combination with Cetuximab
   Tomoyuki Kii et al, 2020, Chemotherapy CrossRef
8. A novel intraperitoneal metastatic xenograft mouse model for survival outcome assessment of esophageal adenocarcinoma
   Md. Sazzad Hassan et al, 2017, PLOS ONE CrossRef
9. Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma
   Md Sazzad Hassan et al, 2018, Translational Oncology CrossRef
10. Animal Model: Xenograft Mouse Models in Esophageal Adenocarcinoma
    Md Sazzad Hassan et al, 2018, Esophageal Adenocarcinoma CrossRef
11. Nanoplatforms: The future of oral cancer treatment
    Kalpani Senevirathna et al, 2023, Health Science Reports CrossRef